Eiichi Kumamoto

Dr. Eiichi Kumamoto

Department of Physiology, Saga Medical School, 5-1-1 Nabeshima, Saga 849-8501, Japan
orcid

Research Focus & Metrics

Academic Career Length

46Years (1981-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 May 2010 in British Journal of Pharmacology
Verified
Journal Article
Open access
PDF file
TKToshifumi Kosugi
Toshifumi Kosugi
KMKotaro Mizuta
Kotaro Mizuta
TFTsugumi Fujita
Tsugumi Fujita
MNMikio Nakashima
Mikio Nakashima
EKEiichi Kumamoto
Eiichi Kumamoto
BACKGROUND AND PURPOSE Dexmedetomidine, an α 2 ‐adrenoceptor agonist, exhibits anti‐nociceptive actions at the spinal cord and enhances the effect of local anaesthetics in the peripheral nervous system. Although the latter action may be attributed in part to inhibition of nerve conduction produced by dexmedetomidine, this has not been fully examined yet. EXPERIMENTAL APPROACH We examined the effects of various adrenoceptor agonists including dexmedetomidine, and tetracaine, a local anaesthetic, on compound action potentials (CAPs) recorded from the frog sciatic nerve, using the air‐gap method. KEY RESULTS Dexmedetomidine reversibly and concentration‐dependently reduced the peak amplitude of CAPs (IC 50 = 0.40 mmol·L −1 ). This action was not antagonized by two α 2 ‐adrenoceptor antagonists, yohimbine and atipamezole; the latter antagonist itself reduced CAP peak amplitude. Clonidine and oxymetazoline, two other α 2 ‐adrenoceptor agonists, also inhibited CAPs; the maximum effect of clonidine was only 20%, while oxymetazoline was less potent (IC 50 = 1.5 mmol·L −1 ) than dexmedetomidine. On the other hand, (±)‐adrenaline, (±)‐noradrenaline, α 1 ‐adrenoceptor agonist (‐)‐phenylephrine and β‐adrenoceptor agonist (‐)‐isoprenaline (each 1 mmol·L −1 ) had no effect on CAPs. Tetracaine reversibly reduced CAP peak amplitude (IC 50 of 0.014 mmol·L −1 ). CONCLUSIONS AND IMPLICATIONS Dexmedetomidine reduced CAP peak amplitude without α 2 ‐adrenoceptor activation (at concentrations >1000‐fold higher than those used as α 2 adrenoceptor agonist), with a lower potency than tetracaine. CAPs were inhibited by other α 2 adrenoceptor agonists, oxymetazoline and clonidine, and also an α 2 adrenoceptor antagonist atipamezole. Thus, some drugs acting on α 2 adrenoceptors are able to block nerve conduction.

1 January 2013 in Molecular Pain
Verified
Journal Article
Open access
PDF file
TLTao Liu
Tao Liu
CJChangyu Jiang
Changyu Jiang
TFTsugumi Fujita
Tsugumi Fujita
SLShi-Wen Luo
Shi-Wen Luo
EKEiichi Kumamoto
Eiichi Kumamoto
Background: Proinflammatory cytokine interleukin-1β (IL-1β) released from spinal microglia plays an important role in the maintenance of acute and chronic pain states. However, the cellular basis of this action remains poorly understood. Using whole-cell patch-clamp recordings, we examined the action of IL-1β on AMPA- and NMDA-receptor-mediated currents recorded from substantia gelatinosa (SG) neurons of adult rat spinal cord slices which are key sites for regulating nociceptive transmission from the periphery. Results: AMPA- and NMDA-induced currents were increased in peak amplitude by IL-1β in a manner different from each other in SG neurons. These facilitatory actions of IL-1β were abolished by IL-1 receptor (IL-1R) antagonist (IL-1ra), which by itself had no detectable effects on AMPA- and NMDA-induced currents. The AMPA- but not NMDA-induced current facilitated by IL-1β was recovered to control level 30 min after IL-1β washout and largely depressed in Na+-channel blocker tetrodotoxin-containing or nominally Ca2+-free Krebs solution. Minocycline, a microglia inhibitor, blocked the facilitatory effect of IL-1β on AMPA- but not NMDA-induced currents, where minocycline itself depressed NMDA- but had not any effects on AMPA-induced currents. Conclusions: IL-1β enhances AMPA and NMDA responses in SG neurons through IL-1R activation; the former but not latter action is reversible and due to an increase in neuronal activity in a manner dependent on extracellular Ca2+ and minocycline. It is suggested that AMPA and NMDA receptors are positively modulated by IL-1β in a manner different from each other; the former but not latter is mediated by a neurotransmitter released as a result of an increase in neuronal activity. Since IL-1β contributes to nociceptive behavior induced by peripheral nerve or tissue injury, the present findings also reveal an important cellular link between neuronal and glial cells in the spinal dorsal horn.

1 January 2014 in Molecular Pain
Verified
Journal Article
Open access
TYToshiharu Yasaka
Toshiharu Yasaka
STSheena Yx Tiong
Sheena Yx Tiong
EPErika Polgár
Erika Polgár
MWMasahiko Watanabe
Masahiko Watanabe
EKEiichi Kumamoto
Eiichi Kumamoto
ATAndrew J Todd
Andrew J Todd
Background: Lamina I projection neurons respond to painful stimuli, and some are also activated by touch or hair movement. Neuropathic pain resulting from peripheral nerve damage is often associated with tactile allodynia (touch-evoked pain), and this may result from increased responsiveness of lamina I projection neurons to non-noxious mechanical stimuli. It is thought that polysynaptic pathways involving excitatory interneurons can transmit tactile inputs to lamina I projection neurons, but that these are normally suppressed by inhibitory interneurons. Vertical cells in lamina II provide a potential route through which tactile stimuli can activate lamina I projection neurons, since their dendrites extend into the region where tactile afferents terminate, while their axons can innervate the projection cells. The aim of this study was to determine whether vertical cell dendrites were contacted by the central terminals of low-threshold mechanoreceptive primary afferents. Results: We initially demonstrated contacts between dendritic spines of vertical cells that had been recorded in spinal cord slices and axonal boutons containing the vesicular glutamate transporter 1 (VGLUT1), which is expressed by myelinated low-threshold mechanoreceptive afferents. To confirm that the VGLUT1 boutons included primary afferents, we then examined vertical cells recorded in rats that had received injections of cholera toxin B subunit (CTb) into the sciatic nerve. We found that over half of the VGLUT1 boutons contacting the vertical cells were CTb-immunoreactive, indicating that they were of primary afferent origin. Conclusions: These results show that vertical cell dendritic spines are frequently contacted by the central terminals of myelinated low-threshold mechanoreceptive afferents. Since dendritic spines are associated with excitatory synapses, it is likely that most of these contacts were synaptic. Vertical cells in lamina II are therefore a potential route through which tactile afferents can activate lamina I projection neurons, and this pathway could play a role in tactile allodynia.

1 October 2006 in British Journal of Pharmacology
Verified
Journal Article
Open access
PDF file
RKR Katsuki
R Katsuki
TFT Fujita
T Fujita
AKA Koga
A Koga
TLT Liu
T Liu
TNT Nakatsuka
T Nakatsuka
EKEiichi Kumamoto
Eiichi Kumamoto
Background and purpose: Although tramadol is known to exhibit a local anaesthetic effect, how tramadol exerts this effect is not understood fully.Experimental approach: The effects of tramadol and its metabolite mono‐O‐demethyl‐tramadol (M1) on compound action potentials (CAPs) were examined by applying the air‐gap method to frog sciatic nerves, and the results were compared with those of other local anaesthetics, lidocaine and ropivacaine.Key results: Tramadol reduced the peak amplitude of the CAP in a dose‐dependent manner (IC50=2.3 mM). On the other hand, M1 (1–2 mM), which exhibits a higher affinity forμ‐opioid receptors than tramadol, did not affect CAPs. These effects of tramadol were resistant to the non‐selective opioid receptor antagonist naloxone and theμ‐opioid receptor agonist, DAMGO, did not affect CAPs. This tramadol action was not affected by a combination of the noradrenaline uptake inhibitor, desipramine, and the 5‐hydroxytryptamine uptake inhibitor, fluoxetine. Lidocaine and ropivacaine also concentration‐dependently reduced CAP peak amplitudes with IC50values of 0.74 and 0.34 mM, respectively.Conclusions and implications: These results indicate that tramadol reduces the peak amplitude of CAP in peripheral nerve fibres with a potency which is less than those of lidocaine and ropivacaine, whereas M1 has much less effect on CAPs. This action of tramadol was not produced by activation ofμ‐opioid receptors nor by inhibition of noradrenaline and 5‐hydroxytryptamine uptake. It is suggested that the methyl group present in tramadol but not in M1 may play an important role in producing nerve conduction block.British Journal of Pharmacology(2006)149, 319–327. doi:10.1038/sj.bjp.0706868

1 March 2014 in Journal of Neurophysiology
Verified
Journal Article
Closed access
PDF file
CJChangyu Jiang
Changyu Jiang
TFTsugumi Fujita
Tsugumi Fujita
EKEiichi Kumamoto
Eiichi Kumamoto
Cellular mechanisms for antinociception produced by oxytocin in the spinal dorsal horn have not yet been investigated thoroughly. We examined how oxytocin affects synaptic transmission in substantia gelatinosa neurons, which play a pivotal role in regulating nociceptive transmission, by applying the whole-cell patch-clamp technique to the substantia gelatinosa neurons of adult rat spinal cord slices. Bath-applied oxytocin did not affect glutamatergic spontaneous, monosynaptically-evoked primary-afferent Aδ-fiber and C-fiber excitatory transmissions. On the other hand, oxytocin produced an inward current at −70 mV and enhanced GABAergic and glycinergic spontaneous inhibitory transmissions. These activities were repeated with a slow recovery from desensitization, concentration-dependent and mimicked by oxytocin-receptor agonist. The oxytocin current was inhibited by oxytocin-receptor antagonist, intracellular GDPβS, U-73122, 2-aminoethoxydiphenyl borate, but not dantrolene, chelerythrine, dibutyryl cyclic-AMP, CNQX, Ca2+-free and tetrodotoxin, while the spontaneous inhibitory transmission enhancements were depressed by tetrodotoxin. Current-voltage relation for the oxytocin current reversed at negative potentials more than the equilibrium potential for K+, or around 0 mV. The oxytocin current was depressed in high-K+, low-Na+or Ba2+-containing solution. Vasopressin V1A-receptor antagonist inhibited the oxytocin current, but there was no correlation in amplitude between a vasopressin-receptor agonist [Arg8]vasopressin and oxytocin responses. It is concluded that oxytocin produces a membrane depolarization mediated by oxytocin but not vasopressin-V1Areceptors, which increases neuronal activity, resulting in the enhancement of inhibitory transmission, a possible mechanism for antinociception. This depolarization is due to a change in membrane permeabilities to K+and/or Na+, which is possibly mediated by phospholipase C and inositol 1,4,5-triphosphate-induced Ca2+-release.

13 March 2015 in Pharmacology Research & Perspectives
Verified
Journal Article
Open access
PDF file
SOSena Ohtsubo
Sena Ohtsubo
TFTsugumi Fujita
Tsugumi Fujita
AMAkitomo Matsushita
Akitomo Matsushita
EKEiichi Kumamoto
Eiichi Kumamoto
Plant‐derived chemicals including aroma oil compounds have an ability to inhibit nerve conduction and modulate transient receptor potential (TRP) channels. Although applying aroma oils to the skin produces a local anesthetic effect, this has not been yet examined throughly. The aim of the present study was to know how nerve conduction inhibitions by aroma oil compounds are related to their chemical structures and whether these activities are mediated byTRPactivation. Compound action potentials (CAPs) were recorded from the frog sciatic nerve by using the air‐gap method. Citral (aldehyde), which activates various types ofTRPchannels, attenuated the peak amplitude ofCAPwith the half‐maximal inhibitory concentration (IC50) value of 0.46 mmol/L. Another aldehyde (citronellal), alcohol (citronellol, geraniol, (±)‐linalool, (−)‐linalool, (+)‐borneol, (−)‐borneol,α‐terpineol), ester (geranyl acetate, linalyl acetate, bornyl acetate), and oxide (rose oxide) compounds also reducedCAPpeak amplitudes (IC50: 0.50, 0.35, 0.53, 1.7, 2.0, 1.5, 2.3, 2.7, 0.51, 0.71, 0.44, and 2.6 mmol/L, respectively). On the other hand, the amplitudes were reduced by a small extent by hydrocarbons (myrcene andp‐cymene) and ketone (camphor) at high concentrations (2–5 mmol/L). The activities of citral and otherTRPagonists ((+)‐borneol and camphor) were resistant toTRPantagonist ruthenium red. An efficacy sequence for theCAPinhibitions was generally aldehydes ≥ esters ≥ alcohols > oxides >> hydrocarbons. TheCAPinhibition by the aroma oil compound was not related to its octanol–water partition coefficient. It is suggested that aroma oil compounds inhibit nerve conduction in a manner specific to their chemical structures withoutTRPactivation.